Gut Microbial Dipeptidyl Peptidase-4 and Associated Prolyl Tripeptidyl Peptidases: A Novel Classification and Response to Inhibitors
Discuss this preprint
Start a discussion What are Sciety discussions?Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
In recent decades, microbiome research has progressed profoundly from exploring microbial diversity to uncovering host-microbial-isozymes (HMI). The understanding of the implications for human health of one such HMI, microbially derived dipeptidyl peptidases, remains limited, despite their structural and functional similarities to human DPP-4 (hDPP-4). In humans, hDPP-4 plays a critical role in several vital processes, including glucose metabolism and immune regulation. Moreover, its structure and inhibition have been well studied. In contrast, putative microbial homologs of hDPP-4 lack precise delineation, classification, and nomenclature, limiting the development of targeted therapeutics. Early evidence indicates that microbial homologs of hDPP-4 may not be effectively inhibited by current therapeutics designed for hDPP-4, underscoring the need for novel approaches to target these microbial enzymes. Using a combination of experimental and computational methods, including in vitro screening of activity and hDPP-4 inhibitor assays across selected bacterial strains, this study establishes the landscape of putative microbial homologs of DPP-4 and closely associated prolyl tripeptidyl‐peptidases. We propose a novel classification of microbial DPP-4 enzymes into four distinct classes. These classes are characterized by structural variations at critical residues, which may render them incompatible with current hDPP-4 targeted therapeutics. Computational studies show molecular distinctions between potential microbial homologs and hDPP-4, highlighting variations that would explain the results of in vitro screening of hDPP-4 inhibitors across various microbial species. These findings demonstrate a high diversity of microbial enzymes structurally similar to hDPP-4 and highlight the need to develop personalized microbial-specific DPP-4 therapeutics that accommodate the unique characteristics of microbial enzymes.